MAP1LC3A and cholangiocarcinoma: To test this hypothesis, we estimated the OS in the cohort of 30 patients subjected to chemotherapy, considering the group bearing a high-LC3-expressing CCA along with low IL-6 in CAFs (regardless of p62 expression) (n = 13) vs. the other combinations (n = 17).